Cabaletta is developing innovative and highly specific engineered T cell therapies for patients with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. The proprietary Cabaletta Approach to selective B cell Ablation (CABA™) platform is focused on eliminating pathogenic B cells that express autoantibodies, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Its CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. It has identified over two dozen B cell-mediated autoimmune diseases where it believes its CABA™ platform may provide a biological opportunity for cure. The lead candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ trial, which is a Phase 1 study for the treatment of patients with mucosal pemphigus vulgaris (mPV).